Screener
Syndax Pharmaceuticals SNDX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of short and long-term investments | (39,387) | (10,538) |
| Proceeds from sales and maturities of short-term investments | 77,777 | 104,680 |
| Net cash provided by investing activities | 38,390 | 94,142 |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from Employee Stock Purchase Plan | 458 | 545 |
| Proceeds from stock option exercises | 7,460 | 385 |
| Net cash provided by financing activities | 7,918 | 930 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's investing cash flow?
- Syndax Pharmaceuticals (SNDX) reported investing cash flow of $38.39M in Q1 2026.
- How has Syndax Pharmaceuticals's investing cash flow changed year-over-year?
- Syndax Pharmaceuticals's investing cash flow decreased by 59.2% year-over-year, from $94.14M to $38.39M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Syndax Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude